131 related articles for article (PubMed ID: 4040985)
1. [Mitoxantrone in the treatment of relapsed and refractory malignant lymphoma].
Kimura I; Ohnoshi T; Hiraki S; Ueoka H; Toyata K; Miyamoto H; Yamane T; Ueno K; Murashima M
Gan No Rinsho; 1985 May; 31(6 Suppl):767-73. PubMed ID: 4040985
[TBL] [Abstract][Full Text] [Related]
2. [A phase II study of mitoxantrone in refractory and relapsed malignant lymphomas. Cooperative Study Group of Mitoxantrone in Malignant Lymphomas].
Kimura I; Ohnoshi T; Ogawa M; Sampi K; Masaoka T; Yamada K; Ohta K; Kitani T; Kawagoe H; Shirakawa S
Gan To Kagaku Ryoho; 1986 Sep; 13(9):2800-6. PubMed ID: 3753026
[TBL] [Abstract][Full Text] [Related]
3. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
4. [Combination chemotherapy with mitoxantrone, etoposide, vindesine and prednisolone for relapsed or refractory malignant lymphoma: presence of cross-resistance to CHOP therapy].
Takagi T; Sakai C; Oguro M
Gan To Kagaku Ryoho; 1992 Jun; 19(6):917-20. PubMed ID: 1605671
[No Abstract] [Full Text] [Related]
5. [Establishment of adriamycin-resistant human small-cell lung cancer cells in culture: analysis of the mechanism of resistance and cross-resistance].
Kimura I; Ohnoshi T; Hiraki S; Miyamoto H
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):830-6. PubMed ID: 3032107
[TBL] [Abstract][Full Text] [Related]
6. [Phase II study of mitoxantrone].
Tada A; Ogawa M; Usui N; Inagaki J; Horikoshi N; Inoue K; Ikeda K; Adachi K; Nakada H; Okada Y
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1649-54. PubMed ID: 6476838
[TBL] [Abstract][Full Text] [Related]
7. [Phase II study of mitoxantrone for hematologic malignancies].
Ueoka H; Ueno K; Yamane T; Toyoda K; Endo H; Nishihara R; Takahashi I; Ohnoshi T; Kitajima K; Kimura I
Gan To Kagaku Ryoho; 1983 Nov; 10(11):2399-402. PubMed ID: 6639101
[TBL] [Abstract][Full Text] [Related]
8. [Combination chemotherapy with BH-AC, mitoxantrone, etoposide, and prednisolone to refractory or relapsed malignant lymphoma].
Satoh T; Tsushima K; Hizawa Y; Nakui Y; Itoh J; Tamura Y; Saitoh S; Taka-mi H; Munakata A; Kawamura S
Gan To Kagaku Ryoho; 1997 Apr; 24(6):733-6. PubMed ID: 9126313
[No Abstract] [Full Text] [Related]
9. [A phase II study of mitoxantrone in malignant lymphoma].
Ibuka T; Sasaki T; Imai K; Sakai Y
Gan To Kagaku Ryoho; 1986 Aug; 13(8):2612-7. PubMed ID: 3740861
[TBL] [Abstract][Full Text] [Related]
10. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL).
Coleman M; Leonard J; Shuster MW; Kaufman TP
Eur J Haematol Suppl; 2001 Jul; 64():41-5. PubMed ID: 11486401
[TBL] [Abstract][Full Text] [Related]
11. [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
Forstpointner R; Hänel A; Repp R; Hermann S; Metzner B; Pott C; Hartmann F; Rothmann F; Böck HP; Wandt H; Unterhalt M; Hiddemann W
Dtsch Med Wochenschr; 2002 Oct; 127(43):2253-8. PubMed ID: 12397539
[TBL] [Abstract][Full Text] [Related]
12. [Mitoxantrone in a combination regimen in advanced breast cancer].
Hausmaninger H
Wien Med Wochenschr; 1985 Dec; 135(23-24):594-7. PubMed ID: 4096006
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
[TBL] [Abstract][Full Text] [Related]
14. [Adriamycin-based combination chemotherapy in the treatment of advanced malignant lymphoma. A progress report].
Sampi K; Honda T; Hattori M
Gan To Kagaku Ryoho; 1984 May; 11(5):1012-7. PubMed ID: 6202245
[TBL] [Abstract][Full Text] [Related]
15. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
[TBL] [Abstract][Full Text] [Related]
16. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[TBL] [Abstract][Full Text] [Related]
17. [Clinical efficacy of a quadruple combination chemotherapy with ACNU, adriamycin, methotrexate, and prednisolone for patients with non-Hodgkin's lymphoma, who were refractory to VEPA (P) treatment].
Niitsu H; Fukuda M; Fukuda S; Takatsu H; Nakayama Y; Hirokawa M; Mamiya S; Miura I; Takahashi F; Yoshida K
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 1):2585-9. PubMed ID: 6594975
[TBL] [Abstract][Full Text] [Related]
18. Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia.
Lee SS; Lee JH; Lee JH; Kim DY; Kim SH; Lim SN; Lee YS; Seol M; Ryu SG; Kang YA; Jang S; Park CJ; Chi HS; Yun SC; Lee KH
Leuk Res; 2009 Apr; 33(4):511-7. PubMed ID: 18819710
[TBL] [Abstract][Full Text] [Related]
19. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
Zinzani PL; Tani M; Molinari AL; Stefoni V; Zuffa E; Alinari L; Gabriele A; Bonifazi F; Salvucci M; Tura S; Baccarani M
Haematologica; 2002 Aug; 87(8):816-21. PubMed ID: 12161357
[TBL] [Abstract][Full Text] [Related]
20. Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial.
Kurbacher CM; Bruckner HW; Cree IA; Kurbacher JA; Wilhelm L; Pöch G; Indefrei D; Mallmann P; Andreotti PE
Clin Cancer Res; 1997 Sep; 3(9):1527-33. PubMed ID: 9815839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
